Clinical Trial Update: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing maximum tolerated dose, safety, and tolerability of a single-dose lanreotide prolonged-release formulation in adults with acromegaly; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• lanreotide prolonged-release formulation (lanreotide)

Snippet

Sponsor: Ipsen | Conditions: Acromegaly | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-04-25